TNF and benign prostatic hyperplasia: Compared to the control group, treatment with myricetin improved the pathohistological signs of BPH and enhanced the antioxidant and anti-inflammatory capacity of the prostatic tissue, as evidenced by its ability to enhance the total antioxidant capacity (TAC) levels and reduce malondialdehyde (MDA) levels, decrease the levels of the inflammatory biomarkers tumor necrosis factor alpha (TNF-α) and interleukin-1 beta (IL1-β) levels, and reduce serum dihydrotestosterone (DHT) levels.